You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 11, 2024

JYNARQUE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Jynarque patents expire, and when can generic versions of Jynarque launch?

Jynarque is a drug marketed by Otsuka and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-six patent family members in twenty-four countries.

The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tolvaptan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Jynarque

A generic version of JYNARQUE was approved as tolvaptan by ALKEM LABS LTD on May 19th, 2020.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for JYNARQUE?
  • What are the global sales for JYNARQUE?
  • What is Average Wholesale Price for JYNARQUE?
Drug patent expirations by year for JYNARQUE
Drug Prices for JYNARQUE

See drug prices for JYNARQUE

Pharmacology for JYNARQUE
Paragraph IV (Patent) Challenges for JYNARQUE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
JYNARQUE Tablets tolvaptan 15 mg, 30 mg, 45 mg, 60 mg, 90 mg 204441 1 2021-04-08

US Patents and Regulatory Information for JYNARQUE

JYNARQUE is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting JYNARQUE

Pharmaceutical solid preparation comprising benzazepines and production method thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing benzazepine compounds or salts thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting JYNARQUE

INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-001 Apr 23, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-003 Apr 23, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-002 Apr 23, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for JYNARQUE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-002 Apr 23, 2018 ⤷  Sign Up ⤷  Sign Up
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-005 Apr 23, 2018 ⤷  Sign Up ⤷  Sign Up
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-004 Apr 23, 2018 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for JYNARQUE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V. Jinarc tolvaptan EMEA/H/C/002788
Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
Authorised no no no 2015-05-27
Otsuka Pharmaceutical Netherlands B.V. Samsca tolvaptan EMEA/H/C/000980
Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH).,
Authorised no no no 2009-08-02
Accord Healthcare S.L.U. Tolvaptan Accord tolvaptan EMEA/H/C/005961
Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Authorised yes no no
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for JYNARQUE

When does loss-of-exclusivity occur for JYNARQUE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 96895
Estimated Expiration: ⤷  Sign Up

Patent: 44744
Estimated Expiration: ⤷  Sign Up

China

Patent: 1273017
Patent: Method of manufacturing benzoazepin compound or its salt
Estimated Expiration: ⤷  Sign Up

Patent: 1967107
Patent: Method of manufacturing benzoazepin compound or its salt
Estimated Expiration: ⤷  Sign Up

Patent: 2219741
Patent: Process for preparing benzazepine compounds or salts thereof
Estimated Expiration: ⤷  Sign Up

Patent: 2746229
Patent: Process for preparing benzazepine compounds or salts thereof
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 11788
Estimated Expiration: ⤷  Sign Up

Patent: 12496
Estimated Expiration: ⤷  Sign Up

Patent: 16082
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 19874
Estimated Expiration: ⤷  Sign Up

Patent: 51319
Estimated Expiration: ⤷  Sign Up

Patent: 61215
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 19874
Patent: PROCEDE DE PREPARATION DE COMPOSES DE BENZAZEPINE OU DE SELS DESDITS COMPOSES (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 51319
Patent: Procédés pour préparer des dérivés d' acide benzoïque (Process for preparing derivatives of benzoic acid)
Estimated Expiration: ⤷  Sign Up

Patent: 61215
Patent: Procédé de préparation de composés de benzazépine ou de leurs sels (Process for preparing benzazepine compounds or salts thereof)
Estimated Expiration: ⤷  Sign Up

Germany

Patent: 2006019882
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 24318
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 44932
Patent: PROCESS FOR PREPARING DERIVATIVES OF BENZOIC ACID
Estimated Expiration: ⤷  Sign Up

Patent: 45835
Patent: 製備苯並氮雜卓化合物或其鹽的方法 (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 48999
Patent: THE PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 72329
Patent: 製備苯並氮雜䓬化合物或其鹽的方法 (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 9481
Patent: תהליך עבור הפקת תרכובות 2,3,4,5-טטרההידרו-h1-1-בנזאזפין או מלחים מזה ותרכובת נקייה מאוד המופקת על ידי תהליך האמור (Process for producing 2,3,4,5-tetrahydro-1h-1- benzazepine compounds or salts thereof and highly pure compounds produced by said process)
Estimated Expiration: ⤷  Sign Up

Patent: 7444
Patent: תהליך עבור תרכובות בנזאפין או מלחים מזה (Process for preparing benzazepine compounds or salts thereof)
Estimated Expiration: ⤷  Sign Up

Patent: 7445
Patent: תהליך עבור ייצור תרכובת חומצה בנזאוית (Process for producing a benzoic acid compound)
Estimated Expiration: ⤷  Sign Up

Patent: 7446
Patent: תכשיר רוקחי המכיל מרכיב פעיל מטוהר מאוד של 7- כלורו - 5 - הידרוקסי- 1- [2-מתיל-4-(2-מתילבנזואיל-אמינו)בנזואיל]-2, 3, 4, 5 - טטראהידרו- h 1 - 1 - בנזאזפין בעל טוהר של יותר מ - 99.5% או מלח שלו, או תכשיר רוקחות של מלח שלו (Pharmaceutical composition comprising as an active ingredient a highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl¬benzoyl¬amino)benzoyl]-2,3,4,5-tetrahydro-1h-1-benzazepine having a purity of more than 99.5 %, or a salt thereof, or a pharmaceutically acceptable salt thereof)
Estimated Expiration: ⤷  Sign Up

Patent: 2396
Patent: תהליך הכנה תרכובת ל 4-(בנזואילאמינו) חומצה בנזואיק או מלחים שלהם (Process for preparing 4-(benzoylamino)benzoic acid compounds or salts thereof)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 46587
Estimated Expiration: ⤷  Sign Up

Patent: 83172
Estimated Expiration: ⤷  Sign Up

Patent: 84164
Estimated Expiration: ⤷  Sign Up

Patent: 93083
Estimated Expiration: ⤷  Sign Up

Patent: 07091738
Patent: METHOD OF MANUFACTURING BENZOAZEPIN COMPOUND OR ITS SALT
Estimated Expiration: ⤷  Sign Up

Patent: 12176979
Patent: METHOD FOR PREPARING BENZAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 12197295
Patent: PROCESS FOR PREPARING BENZOAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 12197296
Patent: PROCESS FOR PRODUCING BENZOAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 14139203
Patent: METHOD OF PRODUCING BENZOAZEPINE COMPOUND OR SALT THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 14205699
Patent: ベンゾアゼピン化合物又はその塩の製造方法 (PRODUCTION METHOD OF BENZOAZEPINE COMPOUND OR SALT THEREOF)
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 19874
Estimated Expiration: ⤷  Sign Up

Patent: 51319
Estimated Expiration: ⤷  Sign Up

Patent: 61215
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 19874
Estimated Expiration: ⤷  Sign Up

Patent: 51319
Estimated Expiration: ⤷  Sign Up

Patent: 61215
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 19874
Estimated Expiration: ⤷  Sign Up

Patent: 51319
Estimated Expiration: ⤷  Sign Up

Patent: 61215
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1019363
Estimated Expiration: ⤷  Sign Up

Patent: 1077329
Estimated Expiration: ⤷  Sign Up

Patent: 1119732
Estimated Expiration: ⤷  Sign Up

Patent: 080039459
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 100132087
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 100133028
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 110029184
Patent: PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 58217
Estimated Expiration: ⤷  Sign Up

Patent: 79153
Estimated Expiration: ⤷  Sign Up

Patent: 27794
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JYNARQUE around the world.

Country Patent Number Title Estimated Expiration
China 103989644 Pharmaceutical solid preparation having benzoazepine and production method thereof ⤷  Sign Up
European Patent Office 2261215 Procédé de préparation de composés de benzazépine ou de leurs sels (Process for preparing benzazepine compounds or salts thereof) ⤷  Sign Up
Germany 602008003816 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for JYNARQUE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0450097 300408 Netherlands ⤷  Sign Up 300408, 20101018, EXPIRES: 20151017
0450097 C300408 Netherlands ⤷  Sign Up PRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
0450097 SPC/GB09/037 United Kingdom ⤷  Sign Up PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.